Counseling sexually active teenagers treated with potential human teratogens.
Adolescents with hemoglobinopathies need daily chelation therapy with drugs which are known or suspected to be teratogenic. The prevention of fetal exposure to such drugs is therefore a major task for health professionals caring for these patients. We describe a pilot program aiming to prevent pregnancy among sexually active adolescents treated with iron chelators in Toronto. Most of them had normal response to GnRH, suggesting endocrinologic fertility, and unlike the literature concerning their healthy peers, all sexually active patients in this study reported use of at least one form of contraception.
Shilalukey
K
K
Motherisk Program, Hospital for Sick Children, Toronto, Canada.
Kaufman
M
M
Bradley
S
S
Francombe
W H
WH
Amankwah
K
K
Goldberg
E
E
Shear
N
N
Olivieri
N F
NF
Koren
G
G
D000293:Adolescent; D000294:Adolescent Behavior; D000755:Anemia, Sickle Cell / Q000188:drug therapy; D003268:Contraception Behavior; D003376:Counseling; D000077543:Deferiprone; D003676:Deferoxamine / Q000627:therapeutic use; D005260:Female; D005298:Fertility / Q000187:drug effects; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use; D011247:Pregnancy; D011728:Pyridones / Q000627:therapeutic use; D012736:Sex Education; D012725:Sexual Behavior; D013723:Teratogens; D017086:beta-Thalassemia / Q000188:drug therapy
D007502:Iron Chelating Agents; D011728:Pyridones; D013723:Teratogens; D000077543:Deferiprone; D003676:Deferoxamine